Our Pricing

Weight Loss Injections Hull: Expert Guide to Prescription Treatments

Published: 29 September 2026

Residents seeking weight loss injections Hull now have access to clinically proven prescription treatments including Mounjaro, Wegovy, and Saxenda through Cured Pharmacy's registered UK service. Our Hull patients benefit from transparent pricing, free online consultations with UK prescribers, and discreet home delivery across East Yorkshire. All treatments require clinical assessment by our GPhC-registered team to ensure safety and suitability.

What Weight Loss Injections Hull Patients Can Access in 2025

Weight loss injections Hull residents can obtain include three primary GLP-1 receptor agonists licensed by the MHRA for chronic weight management: Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide) [1]. These prescription-only medicines work by mimicking natural hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity, leading to significant reductions in body weight when combined with lifestyle modification.

Clinical trials demonstrate that tirzepatide (Mounjaro) produces average weight loss of 15-22.5% of initial body weight over 72 weeks, whilst semaglutide (Wegovy) achieves approximately 15% reduction, and liraglutide (Saxenda) around 8% [2]. At Cured Pharmacy, Hull patients undergo a comprehensive online consultation with our UK-registered prescribers who assess BMI, medical history, contraindications, and weight loss goals before approving treatment. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed from our GPhC-registered facility (9012511).

Our service provides Hull residents with convenient access to weight loss injections without the need for in-person clinic visits. Following prescriber approval, medications are dispensed in discreet packaging and delivered directly to your Hull address, typically within 24-48 hours via tracked courier.

How Weight Loss Injections Hull Services Work at Cured Pharmacy

Accessing weight loss injections Hull through Cured Pharmacy follows a streamlined four-step process designed to meet MHRA and GPhC regulatory standards. First, complete our confidential online medical questionnaire covering your weight history, current medications, cardiovascular health, and previous weight loss attempts. This typically takes under three minutes and provides our prescribers with essential clinical information.

Second, a UK-registered independent prescriber reviews your assessment within 24 hours, evaluating your suitability for GLP-1 therapy based on NICE guidelines and contraindication screening. If approved, your prescription is electronically transmitted to our dispensing pharmacy. Third, our pharmacist team prepares your medication with full patient information leaflets and injection technique guidance. Finally, your weight loss injections are dispatched via secure courier to your Hull address with full tracking.

Hull patients benefit from ongoing clinical support throughout treatment. Our prescribers monitor progress, adjust dosing schedules according to the licensed titration protocols, and provide guidance on managing potential side effects such as nausea or constipation. Follow-up consultations ensure your treatment remains safe and effective as you progress through increasing dose strengths.

Eligibility Criteria for Hull Residents

To qualify for weight loss injections Hull through our service, you must meet specific clinical criteria established by the MHRA and NICE. Adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea), are typically eligible for GLP-1 therapy [3]. Our prescribers assess each Hull patient individually, considering medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Weight Loss Injections Hull Pricing and Transparent Costs

Cured Pharmacy offers weight loss injections Hull with upfront transparent pricing visible before you complete your consultation. Mounjaro (tirzepatide) starts from £124.99 per four-week supply, Wegovy (semaglutide) from £124.99, and Saxenda (liraglutide) from £124.99. New patients receive £20 off their first order using code Weightlossnew, reducing initial costs to £124.99 for Mounjaro starter doses.

Our pricing includes the medication, UK prescriber consultation, dispensing by our registered pharmacist team, and tracked delivery to Hull addresses. There are no hidden fees, membership charges, or recurring subscription costs unless you choose our optional auto-refill service for convenience. We guarantee the lowest UK prices for genuine licensed weight loss injections, sourced directly from MHRA-approved wholesalers.

Hull residents often compare our online pharmacy pricing with local clinic costs, which can exceed £124.99-300 per month for equivalent GLP-1 treatments. Cured Pharmacy's streamlined digital model eliminates physical clinic overheads whilst maintaining full regulatory compliance and clinical safety standards, passing these savings directly to patients across East Yorkshire.

Comparing Weight Loss Injections Hull: Mounjaro vs Wegovy vs Saxenda

When selecting between weight loss injections Hull, understanding the pharmacological differences helps patients and prescribers choose optimal therapy. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, the only medication in this class, offering superior weight loss outcomes compared to single-mechanism GLP-1 agonists [4]. SURPASS clinical trials demonstrated tirzepatide's 15mg dose achieved 22.5% mean body weight reduction over 72 weeks.

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist that produced 14.9% average weight loss in the STEP 1 trial at the 2.4mg maintenance dose [5]. Saxenda (liraglutide) requires daily injections and achieves approximately 8% weight loss, making it suitable for patients preferring daily dosing or those with contraindications to higher-efficacy agents. All three medications require gradual dose escalation over 16-20 weeks to minimise gastrointestinal side effects.

Our Hull prescribers consider individual factors including weight loss targets, injection frequency preference, previous GLP-1 experience, cost considerations, and comorbidity profiles when recommending treatment. Patients with type 2 diabetes may benefit particularly from tirzepatide's dual mechanism, whilst those seeking once-weekly convenience often prefer semaglutide formulations.

Side Effect Profiles Across GLP-1 Therapies

Weight loss injections Hull patients commonly experience transient gastrointestinal effects including nausea (20-40% of users), diarrhoea, constipation, and reduced appetite during initial dose escalation phases [6]. These effects typically diminish within 4-8 weeks as physiological tolerance develops. Our prescribers provide Hull residents with evidence-based management strategies including slower titration schedules, dietary modifications, and anti-emetic medications when clinically appropriate. Serious adverse events such as pancreatitis or gallbladder disease occur rarely (less than 1% incidence) but require immediate medical attention.

Clinical Evidence Supporting Weight Loss Injections Hull Prescribers Recommend

The weight loss injections Hull prescribers at Cured Pharmacy recommend are supported by extensive randomised controlled trial data published in peer-reviewed medical journals. The SURMOUNT-1 trial enrolled 2,539 adults without diabetes, demonstrating that tirzepatide 15mg produced 22.5% mean weight reduction versus 2.4% with placebo over 72 weeks [7]. Participants also experienced significant improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers.

Semaglutide's efficacy was established through the STEP trial programme, with STEP 1 showing 14.9% weight loss at 68 weeks in 1,961 participants receiving 2.4mg weekly doses [5]. Importantly, 86.4% of semaglutide-treated participants achieved at least 5% weight loss (a clinically meaningful threshold), compared to 31.5% receiving placebo. Liraglutide's SCALE trials demonstrated 8% mean weight reduction with the 3mg daily dose.

These trials employed rigorous methodologies including intention-to-treat analyses, validated weight measurement protocols, and comprehensive safety monitoring. Hull patients can be confident that the weight loss injections we prescribe have undergone thorough MHRA evaluation and represent gold-standard pharmacotherapy for obesity management when lifestyle interventions alone prove insufficient.

Getting Started with Weight Loss Injections Hull from Cured Pharmacy

Hull residents ready to begin weight loss injections can initiate their consultation immediately through our secure online platform. Navigate to our weight loss assessment page, complete the confidential medical questionnaire, and our UK prescribers will review your submission within 24 hours. If clinically appropriate, your first prescription will be dispensed and dispatched to your Hull address the same working day.

New patients benefit from comprehensive injection technique guidance, including video demonstrations and written instructions for subcutaneous administration. Mounjaro, Wegovy, and Saxenda all utilise pre-filled pen devices designed for self-injection into the abdomen, thigh, or upper arm. Our pharmacy team provides Hull patients with sharps disposal containers and guidance on safe needle management compliant with local Hull City Council waste regulations.

Ongoing support includes access to our pharmacist helpline (+44 116 4646009) for questions about administration technique, side effect management, or dose progression. Follow-up consultations occur at regular intervals aligned with your dose escalation schedule, ensuring continuous clinical oversight throughout your weight loss journey. Hull patients appreciate our combination of clinical expertise, transparent pricing, and convenient home delivery that eliminates the need for repeated clinic visits whilst maintaining full regulatory compliance and safety standards.

What to Expect During Your First Month

During the initial four weeks of weight loss injections Hull patients receive, expect gradual appetite reduction and modest weight loss of 1-3% as your body adapts to GLP-1 therapy. Starting doses are intentionally low (Mounjaro 2.5mg, Wegovy 0.25mg, Saxenda 0.6mg) to minimise gastrointestinal side effects whilst establishing therapeutic drug levels. Our prescribers advise Hull residents to maintain food diaries, monitor hydration, and report any concerning symptoms during this titration phase. Significant weight loss typically accelerates after reaching maintenance doses at weeks 16-20 of treatment.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Tirzepatide (Mounjaro) for chronic weight management. MHRA. [accessed 29 September 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 29 September 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. [accessed 29 September 2026]
4. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised trial. The Lancet, 398(10295), 143-155. [accessed 29 September 2026]
5. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 29 September 2026]
6. Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563. [accessed 29 September 2026]
7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity in people without diabetes (SURMOUNT-1): a double-blind, randomised controlled trial. The Lancet, 400(10350), 1341-1351. [accessed 29 September 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 29 September 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 29 September 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 29 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.